Physician profile
Peter C Tortora
NPI 1235190984
$17,332.09
in general payments reported to CMS, 2019-2025
51 companies · $2,675 in 2025
The $2,675 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $2,028 · 2021: $2,958 · 2022: $2,408 · 2023: $2,430 · 2024: $2,868 · 2025: $2,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,912 · Education: $61.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,912.18 |
| Education | $61.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,307.14 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $2,036.61 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,716.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,393.32 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,376.50 | 2019-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $858.71 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $844.40 | 2019-2023 | Xarelto |
| Pfizer INC. | $766.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $691.82 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $556.01 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $540.25 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $462.93 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $376.44 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $350.12 | 2019-2024 | Trintellix, Glassia |
| Allergan, INC. | $339.55 | 2019-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Tortora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.